Dana-Farber Cancer Institute

Researchers

• SNSahar Nissim
• SSSarah Sammons

Running trials

• Not yet recruiting

  Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer

  NCT07925333· Phase 2· Beth Israel Deaconess Medical Center· Source

• Not yet recruiting

  Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

  NCT07847957· Phase 1/2· Dana-Farber Cancer Institute· Source

• Not yet recruiting

  Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization

  NCT07569250· University of Colorado, Denver· Source

• Not yet recruiting

  my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

  NCT07516353· Dana-Farber Cancer Institute· Source

• Not yet recruiting

  Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

  NCT07101666· Phase 2· Washington University School of Medicine· Source

• Recruiting

  Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

  NCT07787156· Brigham and Women's Hospital· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

  NCT07137416· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes

  NCT07729150· Dana-Farber Cancer Institute· Source

• Recruiting

  Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

  NCT06917911· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

  NCT07499999· Phase 2· Dana-Farber Cancer Institute· Source

• Recruiting

  Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  NCT07804186· Phase 3· IDEAYA Biosciences· Source

• Not yet recruiting

  Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

  NCT07601100· Phase 1/2· Dana-Farber Cancer Institute· Source

• Recruiting

  Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

  NCT07548476· Dana-Farber Cancer Institute· Source

• Active, not recruiting

  Bladder Preservation or Cystectomy for MIBC

  NCT07821177· Early phase 1· Dana-Farber Cancer Institute· Source

• Recruiting

  Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

  NCT07355335· Phase 1· Massachusetts General Hospital· Source

• Recruiting

  B7-H3.CD28Z.CART in CNS Neoplasms

  NCT07390539· Phase 1· Robbie Majzner· Source

• Not yet recruiting

  Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

  NCT07793994· Dana-Farber Cancer Institute· Source

• Recruiting

  D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

  NCT07624513· Phase 3· Dana-Farber Cancer Institute· Source

• Recruiting

  RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

  NCT07735624· Phase 2· Dana-Farber Cancer Institute· Source

• Recruiting

  Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention

  NCT07662239· Dana-Farber Cancer Institute· Source

• Not yet recruiting

  ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

  NCT07247097· Phase 2· Massachusetts General Hospital· Source

• Recruiting

  Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

  NCT07341867· Phase 1· Andrew Hantel, MD· Source

• Recruiting

  A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

  NCT07383506· Phase 1· Cogent Biosciences, Inc.· Source

• Recruiting

  Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  NCT07755436· Phase 1· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Children's Oncology Group· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07719361· Phase 1· Flare Therapeutics Inc.· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07581184· Phase 1· Aktis Oncology, Inc.· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· Phase 2· Verastem, Inc.· Source

• Recruiting

  Statins to Prevent Cancer Associated Blood Clots

  NCT07303816· Phase 4· Brigham and Women's Hospital· Source

• Recruiting

  Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

  NCT06991361· Phase 1· Sarah Nikiforow, MD· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  NCT07061951· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· Phase 2· Gilead Sciences· Source

• Recruiting

  Multicenter Study for External Validation of the TB-NET Score

  NCT07903532· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  Video Inspired Discussions About Ethical Outcomes in Pediatrics

  NCT06786104· Massachusetts General Hospital· Source

• Recruiting

  A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

  NCT06844383· Phase 2· Prostate Cancer Clinical Trials Consortium· Source

• Recruiting

  Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

  NCT07405190· Phase 2· Massachusetts General Hospital· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Androgen-responsive POSLUMA-guided Intra-prostatic Boost

  NCT07393867· Phase 2· Martin T. King, MD, PhD· Source

• Recruiting

  SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

  NCT07551635· Phase 2· Dana-Farber Cancer Institute· Source

Showing 50 of 968.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers93 recruiting
• Lung cancer76 recruiting
• Ovarian cancer43 recruiting
• Prostate cancer41 recruiting
• Acute myeloid leukaemia38 recruiting
• Colorectal cancer37 recruiting
• Sarcoma36 recruiting
• Metastatic breast cancer34 recruiting
• Endometrial cancer32 recruiting
• Multiple myeloma32 recruiting
• Head and neck cancer31 recruiting
• Pancreatic cancer31 recruiting
• Chronic lymphocytic leukaemia29 recruiting
• Gastric and oesophageal cancer22 recruiting
• Kidney cancer20 recruiting
• Myelodysplastic syndromes20 recruiting
• Triple-negative breast cancer20 recruiting
• Bladder cancer18 recruiting
• Acute lymphoblastic leukaemia16 recruiting
• Glioblastoma16 recruiting
• Melanoma15 recruiting
• Liver and biliary tract cancer14 recruiting
• Myeloproliferative neoplasms14 recruiting
• Brain metastases10 recruiting
• Cervical cancer10 recruiting
• Diffuse large B-cell lymphoma10 recruiting
• Chronic myeloid leukaemia9 recruiting
• Neuroblastoma9 recruiting
• Follicular lymphoma7 recruiting
• Hodgkin lymphoma7 recruiting
• Mantle cell lymphoma7 recruiting
• Neuroendocrine tumours7 recruiting
• Mesothelioma5 recruiting
• Thyroid cancer4 recruiting
• Aplastic anaemia2 recruiting
• Multiple sclerosis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Amyloidosis1 recruiting
• Barrett's oesophagus1 recruiting
• Burkitt lymphoma1 recruiting
• Crohn's disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Down syndrome1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hearing loss1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Insomnia1 recruiting
• Liver cirrhosis1 recruiting
• Lupus (SLE)1 recruiting
• Meningioma1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Testicular cancer1 recruiting
• Thymoma and thymic carcinoma1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Withdrawn

  A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

  NCT07075627· Addario Lung Cancer Medical Institute· Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· Phase 1· SystImmune Inc.· Source

• Completed

  Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention

  NCT07519200· Dana-Farber Cancer Institute· Source

• Withdrawn

  UNTIRE: Cancer-related Fatigue With Digital Treatment

  NCT05584540· Dana-Farber Cancer Institute· Source

• Terminated

  A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

  NCT06704724· Phase 1· Pfizer· Source

• Completed

  PRISM for Depression and Anxiety in Young Adults With Cancer

  NCT06502483· Dana-Farber Cancer Institute· Source

• Terminated

  A Study of PHN-010 in Patients With Advanced Solid Tumors

  NCT06457997· Phase 1· Pheon Therapeutics· Source

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Phase 1· Deciphera Pharmaceuticals, LLC· Source

• Completed

  The PediQUEST Response to Pain Of Children With Neurologic Disability Pilot Randomized Controlled Trial

  NCT06075797· Massachusetts General Hospital· Source

• Terminated

  ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

  NCT06351332· Phase 1· Filipa Lynce, MD· Source

• Completed

  A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

  NCT06131398· Phase 1· Amgen· Source

• Withdrawn

  Marizomib Central Nervous System (CNS)

  NCT05050305· Phase 2· Dana-Farber Cancer Institute· Source

• Completed

  Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

  NCT06004167· Massachusetts General Hospital· Source

• Recruiting

  Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

  NCT05918263· Fred Hutchinson Cancer Center· Source

• Terminated

  Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

  NCT06065059· Phase 1/2· Tango Therapeutics, Inc.· Source

• Terminated

  ZN-c3 + Gemcitabine in Pancreatic Cancer

  NCT06015659· Phase 2· Brandon Huffman, MD· Source

• Terminated

  IMM60 and Pembrolizumab in Melanoma and NSCLC

  NCT05709821· Phase 1/2· iOx Therapeutics· Source

• Terminated

  Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

  NCT05921760· Phase 1/2· Servier Bio-Innovation LLC· Source

• Recruiting

  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT05882058· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

  NCT06052852· Phase 1· Bolt Biotherapeutics, Inc.· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

• Completed

  Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

  NCT05866887· Dana-Farber Cancer Institute· Source

• Terminated

  Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

  NCT05609942· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

  NCT05698199· Phase 1· Immunomic Therapeutics, Inc.· Source

• Terminated

  Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

  NCT05617885· Phase 1· Praful Ravi, MB BCHir, MRCP· Source

• Completed

  A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

  NCT05975073· Phase 1/2· Amgen· Source

• Terminated

  Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

  NCT05935748· Phase 2· NiKang Therapeutics, Inc.· Source

• Terminated

  A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

  NCT05886491· Phase 1/2· Takeda· Source

• Completed

  Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

  NCT05775406· Phase 1· Kymera Therapeutics, Inc.· Source

• Terminated

  A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

  NCT05588440· Phase 1/2· Oncternal Therapeutics, Inc· Source

• Completed

  PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

  NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source

• Terminated

  Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

  NCT05827614· Phase 1· Boundless Bio, Inc.· Source

• Completed

  Sleep Treatment Education Program-1 (STEP-1)

  NCT05519982· Dana-Farber Cancer Institute· Source

• Completed

  PROFAST Intervention in Precursor Multiple Myeloma

  NCT05565638· Dana-Farber Cancer Institute· Source

• Withdrawn

  INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT05359692· Phase 2· Incyte Biosciences International Sàrl· Source

• Terminated

  Testing Obeticholic Acid for Familial Adenomatous Polyposis

  NCT05223036· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  A Study to Investigate LYL845 in Adults With Solid Tumors

  NCT05573035· Phase 1· Lyell Immunopharma, Inc.· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Agenus Inc.· Source

• Completed

  A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

  NCT05668585· Phase 1· C4 Therapeutics, Inc.· Source

• Terminated

  Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

  NCT05682170· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source

• Completed

  Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)

  NCT05358951· Dana-Farber Cancer Institute· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Terminated

  Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT05358249· Phase 1/2· Novartis Pharmaceuticals· Source

• Completed

  Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

  NCT04593277· Fred Hutchinson Cancer Center· Source

• Terminated

  Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

  NCT05569512· Phase 1· Malika Kapadia· Source

• Terminated

  Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

  NCT05027594· Phase 1· Nerviano Medical Sciences· Source

• Completed

  Nirogacestat in Ovarian Granulosa Cell Tumors

  NCT05348356· Phase 2· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  NCT05523947· Phase 1/2· Yuhan Corporation· Source

Showing 50 of 356.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer335 works · 225 trials
• Prostate cancer293 works · 101 trials
• Kidney cancer186 works · 83 trials
• Multiple myeloma150 works · 89 trials
• Melanoma148 works · 83 trials
• Triple-negative breast cancer115 works · 55 trials
• Metastatic breast cancer109 works · 92 trials
• Colorectal cancer107 works · 100 trials
• Ovarian cancer99 works · 101 trials
• Glioblastoma97 works · 60 trials
• Acute myeloid leukaemia83 works · 99 trials
• Pancreatic cancer83 works · 81 trials
• Bladder cancer80 works · 47 trials
• Sarcoma78 works · 111 trials
• Acute lymphoblastic leukaemia68 works · 52 trials
• Brain metastases66 works · 23 trials
• Hodgkin lymphoma63 works · 24 trials
• Childhood cancers60 works · 274 trials
• Chronic lymphocytic leukaemia47 works · 57 trials
• Myelodysplastic syndromes34 works · 57 trials
• Diffuse large B-cell lymphoma31 works · 29 trials
• Sickle cell disease31 works · 5 trials
• Neuroendocrine tumours28 works · 25 trials
• Endometrial cancer28 works · 57 trials
• Neuroblastoma25 works · 38 trials
• Head and neck cancer18 works · 69 trials
• Myeloproliferative neoplasms17 works · 28 trials
• Follicular lymphoma17 works · 22 trials
• Mantle cell lymphoma16 works · 18 trials
• Amyloidosis15 works · 4 trials